This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hisamitsu Pharmaceutical Future Growth

Future criteria checks 0/6

Hisamitsu Pharmaceutical's earnings are forecast to decline at 1.7% per annum while its annual revenue is expected to grow at 4% per year. EPS is expected to grow by 0.2% per annum. Return on equity is forecast to be 4.9% in 3 years.

Key information

-1.7%

Earnings growth rate

0.21%

EPS growth rate

Pharmaceuticals earnings growth	8.7%
Revenue growth rate	4.0%
Future return on equity	4.90%
Analyst coverage	Low
Last updated	25 Apr 2026

Recent future growth updates

Recent updates

Analysis Article • Jan 06

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) shareholders have had their patience rewarded with a 25% share price...

Analysis Article • Jan 05

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analysis Article • Dec 18

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its periodic dividend on the...

Analysis Article • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) periodic dividend will be increasing on the 7th of November to...

Analysis Article • Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will increase its dividend on the 7th of November to ¥60.00, which is...

Analysis Article • Apr 18

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Unsurprisingly, Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) stock price was strong on the back of its healthy...

Analysis Article • Mar 07

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Analysis Article • Feb 17

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analysis Article • Jan 13

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analysis Article • Dec 30

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analysis Article • Nov 27

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will pay a dividend of ¥45.00 on the 26th of May. Based on this...

Analysis Article • Nov 08

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analysis Article • Nov 04

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analysis Article • Oct 17

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) healthy profit numbers didn't contain any surprises for investors. We...

Analysis Article • Sep 16

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...

Analysis Article • Aug 20

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) dividend will be increasing from last year's payment of the same...

Analysis Article • Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be paying its dividend of...

Analysis Article • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analysis Article • Jun 27

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analysis Article • Jun 13

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analysis Article • Apr 09

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

With a price-to-earnings (or "P/E") ratio of 20.9x Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) may be sending...

Analysis Article • Mar 18

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Earnings and Revenue Growth Forecasts

TSE:4530 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
2/28/2029	176,797	13,067	N/A	16,324	1
2/29/2028	167,285	12,014	4,281	14,904	1
2/28/2027	159,685	11,973	5,665	16,289	1
2/28/2026	163,024	19,160	9,428	17,478	N/A
11/30/2025	159,267	19,988	N/A	N/A	N/A
8/31/2025	155,493	19,682	8,355	16,556	N/A
5/31/2025	154,861	19,534	N/A	N/A	N/A
2/28/2025	156,006	21,758	4,991	18,765	N/A
11/30/2024	150,132	15,537	N/A	N/A	N/A
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	N/A	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	N/A	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	N/A	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4530's earnings are forecast to decline over the next 3 years (-1.7% per year).

Earnings vs Market: 4530's earnings are forecast to decline over the next 3 years (-1.7% per year).

High Growth Earnings: 4530's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 4530's revenue (4% per year) is forecast to grow slower than the JP market (6.1% per year).

High Growth Revenue: 4530's revenue (4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4530's Return on Equity is forecast to be low in 3 years time (4.9%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 17:21
End of Day Share Price	2026/05/08 00:00
Earnings	2026/02/28
Annual Earnings	2026/02/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hisamitsu Pharmaceutical Co., Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Akitada Iwasa	Daiwa Securities Co. Ltd.

This company listing is no longer active

Hisamitsu Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 10% to JP¥4,350

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Price target decreased by 15% to JP¥4,250

Recent updates

Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from FTSE All-World Index (USD)

Full year 2026 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 28, 2026

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2026 Results on Apr 13, 2026

New major risk - Revenue and earnings growth

Taiyo Kosan Co., Ltd. completed the acquisition of additional 59.38% stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) from Takasago International Corporation (TSE:4914), Yomeishu Seizo Co.,Ltd. (TSE:2540), The Bank of Saga Ltd. (TSE:8395) and others for approximately ¥250 billion.

Third quarter 2026 earnings released: EPS: JP¥69.15 (vs JP¥62.32 in 3Q 2025)

Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026

New minor risk - Share price stability

Taiyo Kosan Co., Ltd. agreed to acquire a %97.49 stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) in a management buyout transaction for approximately ¥380.6 billion.

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 18%

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00

First half dividend of JP¥60.00 announced

Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥60.00 per share

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Price target decreased by 10% to JP¥4,350

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 3,000,000 shares, representing 4.09% for ¥15,000 million.

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Final dividend increased to JP¥60.00

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Hisamitsu Pharmaceutical Co., Inc. Announces Exiting of Sugiyama, Kosuke as Director

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2026 Results on Oct 09, 2025

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2025 Results on Apr 10, 2025

Upcoming dividend of JP¥45.00 per share

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

Third quarter 2025 earnings released: EPS: JP¥62.32 (vs JP¥48.25 in 3Q 2024)

Hisamitsu Pharmaceutical Co., Inc. Announces Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024